NCT06074107 - Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

June 12, 2020

Primary Completion Date

December 20, 2023

Study Completion Date

December 25, 2023

Conditions

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG

BEBT-908 for injection

The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing